IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow for the year ended December 31

in CHF 1 000

Notes

2023

2022

Cash flows from operating activities

Proceeds from sales of securities

4

449 340

476 186

Purchase of securities

4

(195 711)

(200 687)

Interest receipts

35

4

Payments for services

(35 312)

(44 275)

Income taxes paid

(76)

(97)

Total cash flows from operating activities

218 276

231 131

Cash flows from financing activities

Dividend

(156 311)

(212 242)

Purchase of treasury shares

7

(27 303)

Proceeds from borrowings

5

8 000

Repayment of borrowings

5

(58 100)

Interest payments

(5 802)

(1 726)

Total cash flows from financing activities

(220 213)

(233 271)

Foreign exchange difference

490

1 253

Change in cash and cash equivalents

(1 447)

(887)

Cash and cash equivalents at the beginning of the period

1 948

2 835

Cash and cash equivalents at the end of the period

501

1 948

The notes are an integral part of the consolidated financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer